Comparative Pharmacology
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE CHILDREN S ALLERGY versus SYPRINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE CHILDREN S ALLERGY versus SYPRINE.
AZELASTINE HYDROCHLORIDE CHILDREN'S ALLERGY vs SYPRINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azelastine hydrochloride is a phthalazinone derivative that acts as a selective histamine H1-receptor antagonist. It inhibits the release of histamine and other mediators from mast cells, reduces chemotaxis, and decreases eosinophil activation. It also suppresses leukotriene and cytokine production.
Syprine (trientine hydrochloride) is a chelating agent that forms stable complexes with copper, thereby increasing urinary excretion of copper and reducing pathological copper accumulation in tissues.
Azelastine hydrochloride nasal spray: 1 spray (137 mcg) per nostril twice daily; maximum 2 sprays per nostril twice daily.
250 mg to 500 mg orally 4 times daily, maximum 2000 mg daily.
None Documented
None Documented
Terminal elimination half-life is 22–25 hours in adults; steady state achieved in 3–5 days. In children (6–11 years), half-life is similar (mean 22 hours).
Approximately 48 hours in healthy subjects, reflecting prolonged accumulation with regular dosing, requiring careful monitoring for toxicity.
Primarily renal (approximately 75%), with about 50% as unchanged drug and 25% as metabolites via CYP3A4 and CYP2D6. Fecal excretion accounts for ~20%.
Primarily renal (approximately 50% unchanged within 24 hours after oral administration); biliary/fecal elimination accounts for a minor fraction (less than 10%).
Category C
Category C
Antihistamine
Antihistamine